BMS

ArcherDX said the firms aim to apply minimal residual disease monitoring in clinical-trial protocols and for future therapy optimization.

The funds from this sale of rights to Royalty Pharma will allow Agios to advance IDH inhibitors and other investigational drugs in its pipeline through clinical trials.

The Phase IB trial will test whether UbiVac's cancer vaccine combined with BMS' T cell agonist and Opdivo can stimulate anti-cancer immunity in advanced TNBC patients.

The approval follows another recent approval for the two Bristol Myers Squibb agents without chemotherapy indicated for patients with PD-L1 scores of 1 percent or above. 

Clinicians will be able to use the assay to help identify patients with metastatic NSCLC for treatment with nivolumab and ipilimumab. 

This approval, based on the part 1a results from the Phase III CheckMate-227 trial, is the fifth indication for this drug combination.

Based on the three-year overall survival and PFS rate, Bristol Myers Squibb intends to seek FDA approval for the combination in first-line, PD-L1 positive, NSCLC patients.